

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/502,244	01/28/2005		Peter Carmeliet	DECLE70.003APC	9196
20995	7590	10/18/2005		EXAMINER	
KNOBBE N	MARTE	NS OLSON & I	BOWMAN, AMY HUDSON		
2040 MAIN					
FOURTEENTH FLOOR				ART UNIT	PAPER NUMBER
IRVINE, CA 92614			1635		

DATE MAILED: 10/18/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)						
Office Action Commence	10/502,244	CARMELIET ET AL.						
Office Action Summary	Examiner	Art Unit						
	Amy H. Bowman	1635						
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	TE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	l. lely filed the mailing date of this communication. (35 U.S.C. § 133).						
Status								
1) Responsive to communication(s) filed on 22 Ju	lv 2004.							
· - · · - · · · · · · · · · · · · · · ·	action is non-final.							
3) Since this application is in condition for allowar		secution as to the merits is						
. —	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4)⊠ Claim(s) <u>1-3</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.								
6) Claim(s) is/are rejected.								
7) Claim(s) is/are objected to.	•							
Application Papers								
_								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
11) The oath of declaration is objected to by the Ex	ammer. Note the attached Office	Action of form P1O-152.						
Priority under 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da							
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	atent Application (FTO-132)						

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. Furthermore, under PCT Rule 13.2 the requirement of unity of invention referred to in PCT Rule 13.1 shall be fulfilled only when there is a technical relationship among these inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

The special technical feature of claim 1 is drawn to a method of using a molecule that inhibits the expression and/or activity of prominin-1. Claim 1 is drawn to a method of using prominin-1, but does not recite an active step except for using the molecule. Weigmann et al. teach using an antibody raised against the mouse neuroepithelium to identify prominin. Since Weigmann et al. teach an antibody to prominin, the antibody would inherently be expected to have the activity as claimed. Therefore, there is no special technical feature.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Application/Control Number: 10/502,244

Art Unit: 1635

I. Claims 1 and 2, drawn to a method of using an antibody or any fragment thereof that inhibits the expression and/or activity of prominin-1 for treatment of pathological angiogenesis.

Page 3

- II. Claims 1 and 2, drawn to a method of using a small molecule that inhibits the expression and/or activity of prominin-1 for treatment of pathological angiogenesis.
- III. Claims 1 and 2, drawn to a method of using an RNA aptamer that inhibits the expression and/or activity of prominin-1 for treatment of pathological angiogenesis.
- IV. Claims 1 and 2, drawn to a method of using a peptide that inhibits the expression and/or activity of prominin-1 for treatment of pathological angiogenesis.
- V. Claims 1 and 2, drawn to a method of using a ribozyme that inhibits the expression and/or activity of prominin-1 for treatment of pathological angiogenesis.
- VI. Claims 1 and 2, drawn to a method of using an antisense nucleic acid that inhibits the expression and/or activity of prominin-1 for treatment of pathological angiogenesis.
- VII. Claims 1 and 2, drawn to a method of using a siRNA that inhibits the expression and/or activity of prominin-1 for treatment of pathological angiogenesis.
- VIII. Claim 3, drawn to a method of identifying molecules that comprise a region that specifically binds to prominin-1.

Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy H. Bowman whose telephone number is 571-272-0755.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

Application/Control Number: 10/502,244

Art Unit: 1635

Page 5

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Amy H. Bowman Examiner Art Unit 1635

J.D. SCHULTZ, Ph. PATENT EXAMINER